Detalles de la búsqueda
1.
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Ann Rheum Dis
; 78(2): 192-200, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30396903
2.
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
Ann Rheum Dis
; 79(2): e14, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573653
3.
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al.
Ann Rheum Dis
; 79(4): e37, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30674476
Resultados
1 -
3
de 3
1
Próxima >
>>